Lilly Men's Health Portal

Promoted Content


A Lilly Men’s Health Portal account gives you access to a wide range of tools, educational resources, product information and services to assist you to help your patients with erectile dysfunction (ED) or ED + lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Watch now! Cialis Once-a-day Case Study: Erectile dysfunction in a patient with LUTS associated with BPH.




PILLICON   CIALIS® sample online ordering

file icon Patient screening tools

chaticon Click to chat to Lilly Medical Information

usericon Request a Rep

pdficon GP resources

PBS Information. This product is not available on the PBS.
Please review the full product information (PI) before prescribing.

Full PI is available from
CIALIS® MINIMUM PRODUCT INFORMATION Approved Indication: Erectile dysfunction (ED) and moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult males. Dosage and Administration: ED On-Demand Dosing -10mg or 20mg prior to anticipated sexual activity. Max. 20mg per day. Effective up to 36 hours after dosing and in some patients as early as 16 minutes after dosing. ED and/or LUTS/BPH Once-A-Day Dosing - 5mg once daily, approximately the same time every day. Dose must not exceed 5mg daily. Contraindications: Concomitant use with Nitrates, hypersensitivity to tadalafil or its excipients, unstable cardiovascular disease, myocardial infarction within the last 90 days, unstable angina or angina, New York Heart Association Class 2 or greater heart failure in the last 6 months, uncontrolled arrhythmias, severe or uncontrolled hypertension, stroke within the last 6 months, loss of vision in one eye due to non-arteritic anterior ischaemic optic neuropathy (NAION), *the combination use with guanylate cyclase stimulators may lead to symptomatic hypotension. Precautions: Medical assessment prior to treatment, LUTS/BPH patients rule out prostate cancer and assess cardiovascular conditions, severe renal impairment (CrCl≤50mL/min), severe hepatic insufficiency, risk in patients with pre-existing cardiovascular disease, patients predisposed to priapism, potential risk of hypotensive events ≥ 75 years, sudden loss of vision or decrease/loss of hearing. Interactions: anti-hypertensives, other erectile dysfunction treatments, non-selective alpha[1] blockers, CYP3A4 or HIV protease inhibitors, *Riociguat. Adverse Effects: Very Common (≥10%): dyspepsia, headache. Common (>1% and <10%): flushing, back pain, myalgia, pain in extremity, nasal congestion, gastroesophageal reflux disease, diarrhoea, abdominal pain, upper respiratory tract infection, hypertension. Refer to full PI for a complete list. Please review full PI before prescribing which is available on request from Eli Lilly Australia Pty. Limited. 112 Wharf Road, West Ryde NSW 2114. Based on PI last amended 18 December 2015.

*Please note changes in the Product Information.

Cialis® is a registered trademark of Eli Lilly and company. Eli Lilly Australia Pty Limited. ABN 39 000 233 992. Telephone: 1800 4 LILLY (1800 454 559). 112 Wharf Road, West Ryde NSW 2114. PP-TD-AU-0012. Date of preparation June 2017.